SomaLogic's leaders and managers have deep and diverse expertise in all aspects of biotechnology and a shared commitment to the successful deployment of our technology to the multiple applications it enables.
Byron Hewett joined SomaLogic in December, 2013 after serving most recently as Chairman and CEO at BioBehavioral Diagnostics, Inc. Mr. Hewett previously served as General Manager, President and CEO at Immunicon Corporation. Prior to joining Immunicon, he served as senior Vice President of Sales and Marketing and general manager, North America, for Qiagen. Prior to joining Qiagen, he served as Vice President of Worldwide Marketing in the laboratory testing segment of Bayer Diagnostics (previously Chiron Diagnostics), responsible for strategy and marketing of Bayer's global immunochemistry, hematology, clinical chemistry, high volume urine chemistry, laboratory automation, and information and consulting businesses. He had previously served as Vice President within the US branch of the laboratory testing segment and nucleic acid diagnostics business and as President of the US commercial operations unit for Chiron Diagnostics Mr. Hewett began his business career with Abbott Laboratories advancing to the position of business unit manager in Abbott Laboratories' therapeutic drug monitoring and transplant diagnostics business. Mr. Hewett holds a B.S. from the McIntire School of Commerce at University of Virginia and a Masters in Management from the J.L. Kellogg Graduate School of Management at Northwestern University.
Matthew (“Matt”) Norkunas, M.D., joined SomaLogic as Chief Financial Officer in early 2016. Prior to joining SomaLogic, Matt spent nearly 4 years as a Senior Research Analyst at Marsico Capital Management in Denver, Colorado, where he focused on biotech, pharma, life sciences, and diagnostics companies. While at Marsico, Matt evaluated companies at both the private and public level, spearheading firm participation in a number of capital market transactions for companies in the space, including secondary equity, IPO, crossover, and debt financings.
In addition to his eight years of experience in the venture capital industry, Matt is also a board-certified anesthesiologist. During his medical career, Matt spent three years as the Vice President of New Business Development AABP, a private physician group in New York City. He was voted “teaching attending of the year” by Maimonides (New York) Hospital residents in 2010, and was renowned for his cadaver-lab “teach-ins.” He also actively participated in various clinical trials, published in peer-reviewed journals, and developed two patents (pending) for medical devices. Matt received his anesthesia training at Mount Sinai in New York, and earned his M.D. from the University of Maryland Medical School, his M.B.A. from Columbia University, and his B.A. in Biology from St. Mary’s College of Maryland.
Stephen A. Williams
Steve Williams joined SomaLogic in 2009 as Chief Medical Officer, where he is responsible for the development of the diagnostics pipeline and the “Wellness Chip."
Prior to SomaLogic, in 2007 Steve co-founded Decisionability LLC, a Pharma consultancy and authored the book Decisionability: The Skill to Make Your Decisions Productive, Practical and Painless.
From 1989-2007 Steve was at Pfizer, Inc., initially in the Experimental Medicine group working in Exploratory Clinical Development and subsequently as VP, Worldwide Head, Clinical Technology. From 2003-2007 Steve was on the National Advisory Council for Biomedical imaging and Bioengineering at the National Institutes of Health. He helped to launch the Alzheimer’s Disease NeuroImaging (ADNI) study and was an instigator in the formation of the FDA-FNIH-PhRMA biomarker consortium, serving on the inaugural Executive Committee. Steve led or co-led the PhRMA position papers on “proof of concept”, surrogate endpoints and evidentiary standards for biomarkers and diagnostics.
Steve has degrees in physiology, medicine, surgery and a PhD in medicine and physiology from Charing Cross and Westminster Medical School, (now a part of Imperial College, London), and also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.
Nebojsa Janjic has been the chief science officer at SomaLogic, Inc. since January 2009. Prior to joining SomaLogic, Nebojsa was the CSO at Replidyne, Inc., a biotechnology company focusing on the development of new small-molecule antibacterial agents. Prior to Replidyne, he was senior director of drug discovery at NeXstar Pharmaceuticals. At NeXstar, he was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, the first-in-class FDA-approved treatment for macular degeneration and Innovative Pharmaceutical Product of the Year in 2005. Nebojsa is also an inventor of Fovista™, an aptamer-based antagonist of PDGF-B currently in late-stage clinical trials for use in combination with VEGF inhibitors in macular degeneration. Nebojsa received his bachelor's degree in molecular biology and Ph.D. in physical organic chemistry from the University of Washington in Seattle and completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow.
Steven H. Morrissett
Steve Morrissett joined SomaLogic in December 2011 as chief legal counsel. Prior to joining SomaLogic, Steve was a partner at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, where he concentrated on intellectual property litigation. He has litigated patent, trademark, trade secret, and antitrust cases, advising clients on litigation strategies, contract negotiations, and other technology-related legal matters. His litigations have included electronic, computer, and medical device technologies. Steve has handled all phases of trials and appeals before state and federal courts and has taken many cases to jury or bench trials. He has more than 15 years of experience in managing complex technology-related litigations.
Before joining Finnegan, Steve served as a trial attorney with a business litigation firm in oil and gas, real estate, and business litigations. Steve also gained extensive jury trial experience as a district attorney, supervising a criminal prosecution office, presenting cases to grand juries, and trying major felonies. He obtained additional experience as a trial attorney in civil and criminal cases and supervising attorney with the Utah Attorney General. During his public service, Steve assisted in preparing state and federal legislation and testified before state legislative committees on issues including computer crimes and Internet jurisdiction.
Steve received his bachelor's in physics from Pomona College, and his J.D. from Hastings College of Law, University of California.
Alan Williams joined SomaLogic, Inc. in May 2015 as Chief Informatics Officer where he is responsible for software development, bioinformatics, and IT. Prior to joining SomaLogic, Alan was head of Ion Torrent R&D for Thermo Fisher Scientific. During his 5 years at Ion Torrent he jointly lead numerous instrument, kit, and software development projects and launches. His contributions include the launch of the PGM and Proton sequencing platforms, the Ion Chef automated sample prep system, Torrent Suite and Ion Report software systems, and the FDA-registered PGM Dx system. He also shepherded the R&D team through two acquisitions. From 2000 to 2010 Alan held several positions within the Affymetrix R&D team where he was eventually responsible for all bioinformatics, data analysis, and scientific computing R&D activities as VP of Informatics. He lead the development of a robust genomic anchored expression chip design pipeline, the bioinformatics design of numerous expression and genotyping DNA microarrays including the HG-U133 expression array, and created the strategy and lead the effort around the Affymetrix Power Tools. Alan earned a bachelor’s degree in plant biology from the University of California, Davis and a Ph.D. in molecular, cellular, and developmental biology from the University of California, Riverside.
Ralph Martel joined SomaLogic in May, 2015 as Vice President for Assay Platform Development. He came from Affymetrix where, as Director of Science, he developed and launched products for automated biomarker assays. Previously, Ralph was Chief Technology Officer for the Arizona Biosignature Laboratory at the Critical Path Institute, working on the standardization of biomarker tests for drug development. Before C-Path, he spent eight years at HTG Molecular Diagnostics where he was on the founding team at spin-out and where as VP R&D, he led the commercialization of the company's reagents, consumables, instruments, software, and services, to enable genomics-driven drug discovery and clinical diagnostics. Prior to that, Ralph worked at Ventana Medical Systems, where he was an inventor of Ventana's patented detection kits for automated immunohistochemistry and in situ hybridization and where he developed 12 marketed products that are FDA-cleared for in vitro diagnostics. Ralph graduated from Lehigh University with a B.S. in biochemistry and he received his Ph.D. in biochemistry and his MBA from The University of Arizona.
Teresa Lipcsey joined SomaLogic in January 2015, as Corporate Controller and was promoted to Vice President of Finance in February 2016. Teresa has more than 25 years of financial management experience, including Chief Accounting Officer at a publicly traded company and Corporate Controller at another publicly traded company. Her expertise includes finance and operations management, financing, compliance and mergers and acquisitions. She has been instrumental in taking two companies public while in the corporate controller position.
Teresa began her career in public accounting at Deloitte & Touche. She earned a B.S. in Accounting and Finance from the Robert H. Smith Business School at University of Maryland-College Park and is a CPA and CGMA.
Fintan Steele, VP of Corporate Communications, joined SomaLogic full time in 2011. His background includes more than 25 years of experience in translating and communicating scientific research, particular the science (and its implications) behind the “omics revolution.”
Fintan was previously director of communications and scientific education at the Broad Institute of MIT and Harvard. Prior to Broad, he was VP and Global Head of Communications for the Novartis Institutes of BioMedical Research.
After receiving his Ph.D. in biological sciences from the University of Notre Dame in 1990, Fintan completed post-doctoral studies at the National Institutes of Health and Johns Hopkins School of Medicine. After leaving active research in 1993, Fintan held several editorial positions for public and private scientific publishers, including “News” and “News & Views” editor for Nature Medicine, executive editor of Genomics, founding executive editor of Molecular Therapy and executive editor of Nucleic Acid Therapeutics, the journal of the Oligonucleotide Therapeutics Society.
Fintan also holds a M.Div. degree from the St. Meinrad School of Theology and a Masters in medical ethics and religious studies from Indiana University, where he focused on ethical issues in genetics and medicine.
Mark Messenbaugh serves as SomaLogic's vice president, corporate strategy & development, where he is responsible for developing and structuring key business opportunities and third-party collaborations. Mark joined SomaLogic in 2008. Prior to that, he served as lead director for government relations for the Boys & Girls Clubs of America, where he led strategic initiatives funded by federal, state, and local governments, after starting a partnership between the organization and the office of then-Colorado Attorney General Ken Salazar. In a career spanning business strategy, law, politics, and nonprofit development, Mark has practiced corporate transactional law with the national law firms Arnold & Porter and Davis Polk & Wardwell, led business strategy war games for pharma, served as issues director for Al Gore's Presidential Campaign in 2000, helped write land-use legislation for the Colorado State Senate, and clerked for the U.S. Second Circuit Court of Appeals in New York. Mark earned a bachelor's degree in social studies from Harvard College, studied philosophy on a Fulbright Scholarship to Germany, and received his J.D. from Columbia Law School.
Carrie Mulherin joined SomaLogic in December, 2014, as Vice President of Marketing, Diagnostics., and is responsible for building and directing SomaLogic’s efforts to bring breakthrough diagnostic products to the clinical marketplace.
Most recently, Carrie was VP Marketing and Sales for Pearson, following Pearson’s acquisition of BioBehavioral Diagnostics in August 2013. BioBDx introduced the first-ever objective test for ADHD management. Prior to BioBDx/Pearson, Carrie was Vice President of Marketing and Sales at Immunicon, where she directed strategic planning, corporate / product positioning and executed tactical commercial programs. Carrie also served as general manager for Immunicon Pharma Services, which delivered more than 20 biomarker assay development programs to pharma clients as well as clinical trials testing services to deploy rare cell analysis into more than 100 human clinical trials.
Evan King joined SomaLogic in 2010 as the director of SomaSciences (the division of SomaLogic that offers services to the life sciences industry). Prior to joining SomaLogic, Evan served as the chief operating officer of CPC Clinical Research for seven years. Before that, he served in positions with progressively more authority and responsibility at several pharmaceutical companies including Gilead Sciences, NeXstar Pharmaceuticals, and Allos Therapeutics, mainly in the areas of regulatory affairs and pharmaceutical project management. Evan graduated from University of California at Santa Barbara with a bachelor's degree in biology.
Jennifer Hargrove joined SomaLogic as director of human resources in October of 2012. She has over 20 years of experience in Human Resources, mostly with high technology and biotechnology organizations. Prior to joining SomaLogic, Jennifer was HR Manager at Aircell, a division of Gogo, a telecommunications provider for business aircraft. Her biotechnology experience includes Syntex Labs, Guidant, and Array BioPharma. Her HR experience includes start up pre-public companies and large, well-established public companies. Jennifer has a bachelor's degree in communication from Iowa State University and an MBA from the University of Colorado Denver.
Diana Maul has more than 28 years of experience in the medical device industry. Diana joined SomaLogic in 2008, and most recently was appointed Associate Director of Regulatory Affairs and Quality Assurance. Prior to joining SomaLogic she had previously held a variety of roles including responsibility for research and development, intellectual property, project management, regulatory, and quality roles in 22 years at an IVD manufacturing company, BioStar, Inc. During her time with BioStar the company transitioned from a small privately held company to being acquired acquired by Thermo Electron (now ThermoFisher) and Inverness Medical (now Alere). Diana holds a Bachelor of Science in Chemistry from Colorado State University and a Ph.D. in Biochemistry from the University of Nebraska-Lincoln’s Department of Chemistry.
Preston Brown joined SomaLogic in May of 2014. Preston has extensive experience in assisting emerging companies in developing manufacturing, supply chain and quality management systems that enable the commercial marketing of their products. Most recently, he was Director of Manufacturing for MicroPhage, Inc. Preston's previous experience includes: Director of Operations at Advanced Energy, Head of Operations for BioArray Solutions, Associate Director of Supply Chain for Amgen, as well as various operational leadership roles with Ventana Medical Systems. Preston holds a B.S. in Operations Management and Management Information Systems from the University of Arizona. He has also earned APICS CPIM and ISCEA CLM certifications.